^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAT8008

    i
    Other names: BAT8008, BAT-8008
    Company:
    Bio-Thera Solutions
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    25d
    Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection (clinicaltrials.gov)
    P1, N=182, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> May 2027 | Trial primary completion date: Oct 2024 --> May 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    BAT8008
    7ms
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BAT8008 • BAT1308
    over1year
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Bio-Thera Solutions | N=204 --> 112
    Enrollment change • Metastases
    |
    BAT8008 • BAT1308
    over1year
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=204, Recruiting, Bio-Thera Solutions | N=50 --> 204
    Enrollment change • Metastases
    |
    BAT8008 • BAT1308
    almost2years
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BAT8008 • BAT1308
    almost2years
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Bio-Thera Solutions
    New P1/2 trial
    |
    BAT8008 • BAT1308